Literature DB >> 29399201

Role of prolactin/adenoma maximum diameter and prolactin/adenoma volume in the differential diagnosis of prolactinomas and other types of pituitary adenomas.

Yinxing Huang1, Chenyu Ding2, Fangfang Zhang3, Deyong Xiao4, Lin Zhao1, Shousen Wang1.   

Abstract

The present study aimed to investigate the function of the prolactin/adenoma maximum diameter (PRL/MD) and the prolactin/adenoma volume (PRL/V) in the differential diagnosis of prolactinomas and other types of pituitary adenomas. A total of 118 patients with pituitary adenoma, hyperprolactinemia and a plasma PRL <250 µg/l were enrolled. Clinical data from these patients were retrospectively analyzed. A receiver operating characteristic curve was plotted. The function of PRL, PRL/MD and PRL/V in the differential diagnosis of prolactinomas and other types of pituitary adenomas was compared. The results revealed that a PRL of 55.65 µg/l was the most accurate [sensitivity (SE), 0.800; specificity (SP), 0.716; positive predictive value (PPV), 0.857; negative predictive value (NPV), 0.933; and Youden index (YI), 0.516]. The PRL/MD with the highest diagnostic value was 4.03 µg/(l × mm) (SE, 0.800; SP, 0.898; PPV, 0.727; NVP, 0.929; and YI, 0.698). The PRL/V with the highest diagnostic value was 54.00 µg/(l × cm3) (SE, 0.900; SP, 0.966; PPV, 0.900; NVP, 0.966; and YI, 0.866). The PRL/MD tended to be of higher diagnostic accuracy than PRL, but this difference was not statistically significant (P=0.097). The differentiation ability of PRL/V was significantly stronger than that of PRL (P=0.028). Thus, serum PRL, PRL/MD and PRL/V levels may be able to differentiate prolactinomas from other types of hyperprolactinemia-causing pituitary adenomas prior to treatment. PRL/V may be better than the PRL level in achieving a differential diagnosis, and the optimal PRL/V ratio for differentiating prolactinomas from other types of hyperprolactinemia-causing pituitary adenomas was 54.00 µg/(l × cm3).

Entities:  

Keywords:  differential diagnosis; hyperprolactinemia; pituitary adenoma; prolactin; prolactinomas

Year:  2017        PMID: 29399201      PMCID: PMC5774506          DOI: 10.3892/ol.2017.7462

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  31 in total

1.  [Misleading diagnosis of hyperprolactinemia in women].

Authors:  A-C Paepegaey; L Veron; M-C Wimmer; S Christin-Maitre
Journal:  Gynecol Obstet Fertil       Date:  2016-03-07

2.  Discrimination of prolactinoma from hyperprolactinemic non-functioning adenoma.

Authors:  Jae Won Hong; Mi Kyung Lee; Sun Ho Kim; Eun Jig Lee
Journal:  Endocrine       Date:  2009-11-14       Impact factor: 3.633

3.  [Influence of hyperprolactinemia and tumoral size in the postoperative pituitary function in clinically nonfunctioning pituitary macroadenomas].

Authors:  Ana Luiza Vidal Fonseca; Leila Chimelli; Mario José C Felippe Santos; Alair Augusto S M Damas dos Santos; Alice Helena Dutra Violante
Journal:  Arq Neuropsiquiatr       Date:  2002-09       Impact factor: 1.420

4.  Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients.

Authors:  L Vilar; M C Freitas; L A Naves; L A Casulari; M Azevedo; R Montenegro; A I Barros; M Faria; G C Nascimento; J G Lima; L H Nóbrega; T P Cruz; A Mota; A Ramos; A Violante; A Lamounier Filho; M R Gadelha; M A Czepielewski; A Glezer; M D Bronstein
Journal:  J Endocrinol Invest       Date:  2008-05       Impact factor: 4.256

5.  The relationship between serum prolactin and immunocytochemical staining for prolactin in patients with pituitary macroadenomas.

Authors:  R J Ross; A Grossman; P Bouloux; L H Rees; I Doniach; G M Besser
Journal:  Clin Endocrinol (Oxf)       Date:  1985-09       Impact factor: 3.478

6.  Magnetic resonance imaging measurements of pituitary stalk compression and deviation in patients with nonprolactin-secreting intrasellar and parasellar tumors: lack of correlation with serum prolactin levels.

Authors:  M V Smith; E R Laws
Journal:  Neurosurgery       Date:  1994-05       Impact factor: 4.654

7.  Non-functioning pituitary adenomas: clinical feature, laboratorial and imaging assessment, therapeutic management and outcome.

Authors:  Maria Licia Calado de Aguiar Ribeiro Cury; Juliana Coutinho Fernandes; Hélio Rubens Machado; Lucila Leico Elias; Ayrton Custódio Moreira; Margaret de Castro
Journal:  Arq Bras Endocrinol Metabol       Date:  2009-02

8.  Dynamics of prolactin secretion in patients with hypopituitarism and pituitary macroadenomas.

Authors:  B M Arafah; K E Nekl; R S Gold; W R Selman
Journal:  J Clin Endocrinol Metab       Date:  1995-12       Impact factor: 5.958

Review 9.  Update on prolactinomas. Part 2: Treatment and management strategies.

Authors:  Anni Wong; Jean Anderson Eloy; William T Couldwell; James K Liu
Journal:  J Clin Neurosci       Date:  2015-08-01       Impact factor: 1.961

10.  Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline.

Authors:  Nazir A Pala; Bashir A Laway; Raiz A Misgar; Rayees A Dar
Journal:  Diabetol Metab Syndr       Date:  2015-11-14       Impact factor: 3.320

View more
  4 in total

1.  Tumor volume improves preoperative differentiation of prolactinomas and nonfunctioning pituitary adenomas.

Authors:  Kyla Wright; Matthew Lee; Natalie Escobar; Donato Pacione; Matthew Young; Girish Fatterpekar; Nidhi Agrawal
Journal:  Endocrine       Date:  2021-05-08       Impact factor: 3.633

2.  A scoping review to understand the indications, effectiveness, and limitations of cabergoline in radiological and biochemical remission of prolactinomas.

Authors:  Rakesh Mishra; Subhas K Konar; Adesh Shrivastava; Pradeep Chouksey; Sumit Raj; Amit Agrawal
Journal:  Indian J Endocrinol Metab       Date:  2022-02-17

3.  Diagnostic criteria of small sellar lesions with hyperprolactinemia: Prolactinoma or else.

Authors:  Anna Cho; Greisa Vila; Wolfgang Marik; Sigrid Klotz; Stefan Wolfsberger; Alexander Micko
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-06       Impact factor: 6.055

Review 4.  Metabolic effects of prolactin and the role of dopamine agonists: A review.

Authors:  Polly Kirsch; Jessica Kunadia; Shruti Shah; Nidhi Agrawal
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-30       Impact factor: 6.055

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.